Thirty-Day Mortality of Persistent Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia: Insights from a Retrospective Cohort Study.

ABSTRACT: Although glycopeptides remain the preferred treatment for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, the treatment of persistent MRSA bacteremia has been challenging. We investigated real-world treatment strategies for persistent MRSA bacteremia, with a specific emphasis on the use of antimicrobial agents and the frequency of changes during the treatment course. We retrospectively identified patients with persistent MRSA bacteremia in four university-affiliated hospitals between 2017 and 2021. The primary objective of this study was to investigate the patterns of antimicrobial uses for MRSA bacteremia. The secondary objectives were evaluating the associated factors with 1) overall 30-day mortality and 2) changing agents during the treatment course. Time-dependent

SUBMITTER: Jeon M 

PROVIDER: S-EPMC11605044 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature